Radium-223 for men with hormone-refractory prostate cancer and bone metastases
- PMID: 17613416
- DOI: 10.1016/S1470-2045(07)70180-8
Radium-223 for men with hormone-refractory prostate cancer and bone metastases
Comment on
-
Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study.Lancet Oncol. 2007 Jul;8(7):587-94. doi: 10.1016/S1470-2045(07)70147-X. Lancet Oncol. 2007. PMID: 17544845 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
